Nintedanib Zentiva (Nintedanib Esylate)

Nintedanib, the active ingredient in Nintedanib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed to treat idiopathic pulmonary fibrosis and other fibrotic lung conditions in adult patients.

GNH USA supplies Nintedanib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib acts on multiple fibrotic and oncologic pathways, providing therapeutic benefit in several lung‑related disease groups. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity in affected patients. - Non‑small cell lung cancer (in combination with chemotherapy): enhances treatment response when used with standard chemotherapy regimens.

Nintedanib may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and less frequent events.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of queasiness, may occur with or without vomiting. - Decreased appetite: reduced desire to eat, potentially leading to weight loss. - Elevated liver enzymes: increased ALT/AST levels detected on laboratory testing.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring discontinuation. - Bleeding events: gastrointestinal or other bleeding, especially with anticoagulants. - Cardiovascular events: hypertension or arterial thrombotic episodes. - Severe infections: opportunistic infections in immunocompromised patients.

Before initiating therapy, clinicians should evaluate several safety considerations. - Dose adjustment: assess renal or hepatic impairment and modify dose accordingly. - Bleeding risk: monitor patients receiving anticoagulants or antiplatelet agents. - Cardiovascular monitoring: check blood pressure and watch for signs of hypertension. - Liver function: obtain baseline tests and repeat periodically during treatment. - Pregnancy: avoid use as safety in pregnancy and lactation is unknown. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nintedanib exposure and toxicity. - Anticoagulants: concurrent use can heighten bleeding risk. - Other tyrosine kinase inhibitors: combined use may amplify adverse effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may reduce nintedanib plasma levels and effectiveness. - P‑glycoprotein inhibitors: can raise plasma concentrations, requiring observation. - Diuretics: monitor for dehydration and renal function changes.